Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns

Executive Summary

Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.

Advertisement

Related Content

CAR-T Update: Kite's Filing Coming Soon
Juno ROCKETs On Fast Clinical Hold Resolution
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy
Kite And Juno Threatened By Cellectis' Off-The-Shelf CAR-T Success
Companies Clearing Cell And Gene Therapy Manufacturing Hurdles

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register